Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Goaweighon Feb 16, 2021 5:15pm
325 Views
Post# 32579928

RE:I fail to understand

RE:I fail to understand The $ 6 handle scares most retail away. Goodness most retail investors are still looking for sub .50 regardless of what the deal is. I guess Pot and Green deals have changed that mentality a bit but I suspect that most will look at $ 6 and figure they missed the boat by $ 5.50.
It's always price first, market cap second. And even if you got in earlier, let's say at sub .40 pre roll back, which is $ 4.00 now, it's still pscologically difficult to keep buying well into the $ 6's ever if the Cap is still ridiculously low.
I've been waiting for these very events to happen for maybe 3 years now. Owned it at .40, got sick of waiting, sold, and bought it all back and more at $ 4.00 just recently and I know I should be buying it until blood comes out my ears but I'm like a deer in the headlights watching in horror as it keeps going higher....even tho I want it to.
So that's why we're under valued, everyone's in a state of shock because it's all happening too fast now. LOL !

Marky1 wrote: Why everyone here is under valuing ATE...We have Don who just completed a 4B$ USD deal

working for us. I am sure that he is drawing up a deal with Bayer as we speak! We have a brilliant
man who is world renowned and cited in references more than 95% of the worlds scientists... The minimum I see us at is 50$....the NSAIDS business has been waiting 50 years now for a product that we own...I agree with the Crow ( thank you )....other NSAIDS will be removed from the market when Bayer comes out with  super Alleve with no GI problems, at 1/4 the dose...faster acting, longer acting....in short BETTER than any other Medication
we have the science behind us,  we have the math behind us(P values ) we have the perfect people behind us'
anyways, stay long everyone...we have an absolute winner!


<< Previous
Bullboard Posts
Next >>